1. Academic Validation
  2. Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)

Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)

  • Anticancer Res. 2020 Aug;40(8):4471-4479. doi: 10.21873/anticanres.14452.
Riri Yokota 1 Shun Hashimoto 2 Ikuko Watanabe 2 Satoshi Kishimoto 2 Masaaki Toyama 1 Mika Okamoto 1 Makoto Yoshimitsu 3 Kenji Ishitsuka 3 Yuji Ito 2 Masanori Baba 4
Affiliations

Affiliations

  • 1 Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
  • 2 Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
  • 3 Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • 4 Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan m-baba@m2.kufm.kagoshima-u.ac.jp.
Abstract

Background/aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by Infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity.

Materials and methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the Anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay.

Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells.

Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL.

Keywords

ATL; HTLV-1; antibody drug conjugate; cancer chemotherapy; immunotherapy.

Figures
Products